Clinical significance of monocyte heterogeneity

Clinical and Translational Medicine - Tập 4 Số 1 - 2015
Brian K. Stansfield1, David A. Ingram2,3,4
1Department of Pediatrics and Neonatal-Perinatal Medicine, Georgia Regents University, Augusta, Georgia
2Department of Biochemistry and Molecular Biology, Indiana University School of Medicine, 699 Riley Hospital Drive, RR208, 46202 Indianapolis, IN, USA
3Department of Pediatrics and Neonatal-Perinatal Medicine, Indiana University School of Medicine, Indianapolis, Indiana, USA
4Herman B. Wells Center for Pediatric Research, Georgia Regents University, Augusta, Georgia

Tóm tắt

AbstractMonocytes are primitive hematopoietic cells that primarily arise from the bone marrow, circulate in the peripheral blood and give rise to differentiated macrophages. Over the past two decades, considerable attention to monocyte diversity and macrophage polarization has provided contextual clues into the role of myelomonocytic derivatives in human disease. Until recently, human monocytes were subdivided based on expression of the surface marker CD16. “Classical” monocytes express surface markers denoted as CD14++CD16− and account for greater than 70% of total monocyte count, while “non‐classical” monocytes express the CD16 antigen with low CD14 expression (CD14+CD16++). However, recognition of an intermediate population identified as CD14++CD16+ supports the new paradigm that monocytes are a true heterogeneous population and careful identification of specific subpopulations is necessary for understanding monocyte function in human disease. Comparative studies of monocytes in mice have yielded more dichotomous results based on expression of the Ly6C antigen. In this review, we will discuss the use of monocyte subpopulations as biomarkers of human disease and summarize correlative studies in mice that may yield significant insight into the contribution of each subset to disease pathogenesis.

Từ khóa


Tài liệu tham khảo

10.1182/blood.V74.7.2527.2527

10.1084/jem.167.2.408

10.1126/science.1698311

10.1182/blood-2010-02-258558

Heimbeck I, 2010, Standardized single‐platform assay for human monocyte subpopulations: lower CD14 + CD16++ monocytes in females, J Int Soc Anal Cytol, 77, 823, 10.1002/cyto.a.20942

10.1111/j.1365-3083.2007.02051.x

10.4049/jimmunol.168.7.3536

10.1084/jem.20022156

10.1160/TH04-02-0095

10.1182/blood.V82.10.3170.3170

10.1002/ibd.20025

Mayer A, 2011, Support of HUVEC proliferation by pro‐angiogenic intermediate CD163+ monocytes/macrophages: a co‐culture experiment, Clin Hemorheol Microcirc, 49, 423, 10.3233/CH-2011-1492

10.1182/blood-2011-01-326827

10.1016/j.immuni.2010.08.012

10.1084/jem.20011608

10.1007/s12026-012-8297-3

10.1016/j.it.2007.09.004

10.4049/jimmunol.178.11.7405

10.1182/blood-2010-12-326355

10.1182/blood.V87.1.373.373

10.1002/art.33418

10.1189/jlb.0209082

10.1038/ki.2011.433

10.1016/j.imbio.2012.07.001

10.1189/jlb.0307191

10.1172/JCI28549

10.1172/JCI29919

10.1172/JCI40310

10.1084/jem.20032152

10.1038/ni.2405

10.1182/blood-2007-06-098327

Weiner LM, 1994, Phase I trial of recombinant macrophage colony‐stimulating factor and recombinant gamma‐interferon: toxicity, monocytosis, and clinical effects, Cancer Res, 54, 4084

10.1182/blood-2012-02-412551

10.1084/jem.20080421

10.1084/jem.20101387

10.1161/CIRCRESAHA.114.303204

10.1172/JCI29950

10.1038/nm.3258

10.1007/s00281-013-0409-1

10.1007/s00281-013-0387-3

10.1182/blood-2009-07-235028

10.4049/jimmunol.172.7.4410

10.4049/jimmunol.178.4.2000

10.1161/CIRCRESAHA.110.227454

10.1126/science.1175202

10.1084/jem.20061011

10.1161/01.CIR.81.4.1161

10.1016/j.jacc.2009.04.021

10.1016/j.jacc.2012.07.019

10.1084/jem.20070885

10.4049/jimmunol.1300725

10.1016/j.ahj.2011.09.002

10.1253/circj.CJ-09-1045

10.1016/j.jacc.2009.08.089

10.1111/j.1538-7836.2011.04603.x

10.1038/jcbfm.2009.25

10.1161/STROKEAHA.108.532085

10.1371/journal.pone.0069409

10.1161/CIRCULATIONAHA.107.745091

10.1161/CIRCULATIONAHA.111.061986

10.1161/CIRCULATIONAHA.107.743872

10.1161/01.ATV.16.12.1437

10.1016/S0021-9150(99)00061-1

10.1161/ATVBAHA.111.230979

10.3109/07853890.2014.931101

10.1007/s11239-014-1083-4

10.1016/j.atherosclerosis.2010.06.025

10.1016/j.metabol.2010.05.002

10.1161/ATVBAHA.114.304172

10.1093/eurheartj/ehq371

10.1038/29788

10.1161/ATVBAHA.108.165423

10.1161/01.ATV.0000253886.44609.ae

10.1161/CIRCULATIONAHA.107.753558

10.1038/nrneph.2012.41

10.1161/01.STR.0000075294.98582.2F

10.1016/S0140-6736(05)67663-5

10.1093/eurheartj/ehp308

10.1381/096089202762552674

10.1381/096089202321088101

10.1172/JCI57559

10.1161/ATVBAHA.112.301080

10.1161/CIRCRESAHA.113.301112

10.1161/ATVBAHA.114.303029

10.1161/ATVBAHA.114.303983

10.1161/ATVBAHA.114.303030

10.1161/ATVBAHA.114.303033

10.1161/ATVBAHA.114.303031

10.1161/01.ATV.0000188508.40052.35

10.1016/j.atherosclerosis.2006.05.050

10.1161/CIRCULATIONAHA.111.020982

10.1038/nrneph.2010.143

10.1038/sj.ki.5002744

10.1093/ndt/gfq012

10.1111/j.1600-6143.2007.02035.x

10.1093/ndt/gfp287

Ghigliotti G, 2013, CD16(+) monocyte subsets are increased in large abdominal aortic aneurysms and are differentially related with circulating and cell‐associated biochemical and inflammatory biomarkers, Dis Markers, 34, 131, 10.1155/2013/836849

10.1161/ATVBAHA.109.187732

10.1002/jlb.45.6.503

10.1093/ndt/gfr767

10.1002/1529-0131(200006)43:6<1233::AID-ANR6>3.0.CO;2-9

10.1002/art.20219

Benucci M, 2012, Determinants of risk infection during therapy with anti TNF‐alpha blocking agents in rheumatoid arthritis, Rheumatol J, 6, 33

Abeles RD, 2012, CD14, CD16 and HLA‐DR reliably identifies human monocytes and their subsets in the context of pathologically reduced HLA‐DR expression by CD14(hi) /CD16(neg) monocytes: expansion of CD14(hi) /CD16(pos) and contraction of CD14(lo) /CD16(pos) monocytes in acute liver failure, J Int Soc Anal Cytol, 81, 823, 10.1002/cyto.a.22104

10.1371/journal.pone.0028918

10.1111/j.1572-0241.2007.01714.x

10.1111/j.1365-2249.2010.04177.x

10.1002/path.1245

10.1111/j.1749-6632.2009.04738.x

10.1189/jlb.0113021

10.1186/ar2915

10.1016/j.imlet.2013.03.004

Thông tin
Thông tin xuất bản

Clinical and Translational Medicine

Tập 4 Số 1

Thông tin tác giả